Polypeptides and antibodies

An isolated polypeptide comprising at least one complementarity determining region (CDR) selected from:

• amino acids 26 to 35 of SEQ ID NO:
• 2;
• amino acids 50 to 66 of SEQ ID NO:
• 2;
• amino acids 99 to 110 of SEQ ID NO:
• 2;
• amino acids 26 to 37 of SEQ ID NO:
• 4;
• amino acids 52 to 67 of SEQ ID NO:
• 4;
• amino acids 100 to 109 of SEQ ID NO:
• 4;
• amino acids 26 to 37 of SEQ ID NO:
• 6;
• amino acids 52 to 67 of SEQ ID NO:
• 6;
• amino acids 100 to 109 of SEQ ID NO:
• 6;
• amino acids 26 to 37 of SEQ ID NO:
• 8;
• amino acids 52 to 67 of SEQ ID NO:
• 8;
• amino acids 100 to 109 of SEQ ID NO:
• 8;
• amino acids 26 to 35 of SEQ ID NO:
• 10;
• amino acids 50 to 66 of SEQ ID NO:
• 10;
• amino acids 99 to 110 of SEQ ID NO:
• 10;
• amino acids 26 to 35 of SEQ ID NO:
• 12;
• amino acids 50 to 66 of SEQ ID NO:
• 12;
• amino acids 99 to 111 of SEQ ID NO:
• 12;
• amino acids 26 to 35 of SEQ ID NO:
• 14;
• amino acids 50 to 65 of SEQ ID NO:
• 14;
• amino acids 98 to 111 of SEQ ID NO:
• 14;
• amino acids 26 to 37 of SEQ ID NO:
• 16;
• amino acids 52 to 67 of SEQ ID NO:
• 16;
• amino acids 100 to 109 of SEQ ID NO:
• 16;
• amino acids 26 to 35 of SEQ ID NO:
• 18;
• amino acids 50 to 66 of SEQ ID NO:
• 18;
• amino acids 99 to 105 of SEQ ID NO:
• 18;
• amino acids 26 to 35 of SEQ ID NO:
• 20;
• amino acids 50 to 66 of SEQ ID NO:
• 20;
• amino acids 99 to 118 of SEQ ID NO:
• 20;
• amino acids 26 to 35 of SEQ ID NO:
• 22;
• amino acids 50 to 66 of SEQ ID NO:
• 22;
• amino acids 99 to 118 of SEQ ID NO:
• 22;
• amino acids 26 to 35 of SEQ ID NO:
• 24;
• amino acids 50 to 65 of SEQ ID NO:
• 24;
• amino acids 98 to 108 of SEQ ID NO:
• 24;
• amino acids 26 to 35 of SEQ ID NO:
• 26;
• amino acids 50 to 66 of SEQ ID NO:
• 26;
• amino acids 99 to 110 of SEQ ID NO:
• 26;
• amino acids 26 to 35 of SEQ ID NO:
• 28;
• amino acids 50 to 66 of SEQ ID NO:
• 28;
• amino acids 99 to 117 of SEQ ID NO:
• 28;
• amino acids 26 to 37 of SEQ ID NO:
• 30;
• amino acids 52 to 67 of SEQ ID NO:
• 30;
• amino acids 100 to 111 of SEQ ID NO:
• 30;
• amino acids 26 to 37 of SEQ ID NO:
• 32;
• amino acids 52 to 67 of SEQ ID NO:
• 32;
• amino acids 100 to 111 of SEQ ID NO:
• 32;
• amino acids 26 to 37 of SEQ ID NO:
• 34;
• amino acids 52 to 67 of SEQ ID NO:
• 34;
• and
• amino acids 100 to 111 of SEQ ID NO:
• 34;
• wherein the polypeptide, in association with an antibody light chain, binds TR-2.

An isolated polypeptide comprising at least one complementarity determining region (CDR) selected from CDR1b, CDR2b, and CDR3b

• wherein CDR1b comprises the amino acid sequence a1 b1 c1 d1 e1 f1 g1 h1 i1 j1 k1 l1 m1 n1 o1 p1 q1, wherein amino acid a1 is selected from arginine or lysine;
• amino acid b1 is selected from threonine, alanine, or serine;
• amino acid c1 is serine;
• amino acid d1 is glutamine;
• amino acid e1 is selected from serine or glycine;
• amino acid f1 is selected from isoleucine, leucine, or valine;
• amino acid g1 is selected from serine, leucine, or arginine;
• amino acid h1 is selected from threonine, serine, isoleucine, asparagine, arginine, histidine, or tyrosine;
• amino acid i1 is selected from tyrosine, arginine, tryptophan, aspartic acid, or serine;
• j1 is selected from leucine, isoleucine, asparagine, tyrosine, or serine;
• amino acid k1 is selected from asparagine, glycine, valine, alanine, or leucine;
• amino acid l1 is selected from tyrosine, alanine, or asparagine, or is not present;
• amino acid m1 is selected from asparagine or lysine, or is not present;
• amino acid n1 is selected from tyrosine, asparagine, or isoleucine, or is not present;
• amino acid o1 is selected from leucine or tyrosine, or is not present;
• amino acid p1 is selected from aspartic acid or leucine, or is not present;
• and amino acid q1 is selected from valine, alanine, or threonine, or is not present;
• wherein CDR2b comprises the amino acid sequence r1 s1 t1 u1 v1 w1 x1, wherein amino acid r1 is selected from alanine, aspartic acid, leucine, tryptophan, glycine, or valine;
• amino acid s1 is selected from threonine, valine, glycine, or alanine;
• amino acid t1 is serine;
• amino acid u1 is selected from serine, asparagine, or threonine;
• amino acid v1 is selected from leucine, phenylalanine, or arginine;
• amino acid w1 is selected from glutamine, alanine, or glutamic acid;
• and amino acid x1 is selected from serine, arginine, or threonine;
• wherein CDR3b comprises the amino acid sequence y1 z1 a1′ b1′ c1′ d1′ e1′ f1′ g1′, wherein amino acid y1 is selected from glutamine, methionine, leucine, or histidine;
• amino acid z1 is selected from glutamine or lysine;
• amino acid a1′ is selected from serine, threonine, alanine, histidine, tyrosine, or phenylalanine;
• amino acid b1′ is selected from tyrosine, leucine, asparagine, or glycine;
• amino acid c1′ is selected from serine, glutamine, isoleucine, or lysine;
• amino acid d1′ is selected from threonine, phenylalanine, tyrosine, alanine, or serine;
• amino acid e1′ is proline;
• amino acid f1′ is selected from leucine, phenylalanine, tryptophan, serine, or arginine;
• and amino acid g1′ is selected from threonine or serine;
• and
• wherein the polypeptide, in association with an antibody heavy chain, binds TR-2.

An isolated polypeptide comprising at least one complementarity determining region (CDR) selected from:

• amino acids 24 to 34 of SEQ ID NO:
• 36;
• amino acids 50 to 56 of SEQ ID NO:
• 36;
• amino acids 89 to 97 of SEQ ID NO:
• 36;
• amino acids 24 to 34 of SEQ ID NO:
• 38;
• amino acids 50 to 56 of SEQ ID NO:
• 38;
• amino acids 89 to 97 of SEQ ID NO:
• 38;
• amino acids 24 to 34 of SEQ ID NO:
• 40;
• amino acids 50 to 56 of SEQ ID NO:
• 40;
• amino acids 89 to 97 of SEQ ID NO:
• 40;
• amino acids 24 to 34 of SEQ ID NO:
• 42;
• amino acids 50 to 56 of SEQ ID NO:
• 42;
• amino acids 89 to 97 of SEQ ID NO:
• 42;
• amino acids 24 to 34 of SEQ ID NO:
• 44;
• amino acids 50 to 56 of SEQ ID NO:
• 44;
• amino acids 89 to 97 of SEQ ID NO:
• 44;
• amino acids 24 to 34 of SEQ ID NO:
• 46;
• amino acids 50 to 56 of SEQ ID NO:
• 46;
• amino acids 89 to 97 of SEQ ID NO:
• 46;
• amino acids 24 to 40 of SEQ ID NO:
• 48;
• amino acids 56 to 62 of SEQ ID NO:
• 48;
• amino acids 95 to 103 of SEQ ID NO:
• 48;
• amino acids 24 to 39 of SEQ ID NO:
• 50;
• amino acids 55 to 61 of SEQ ID NO:
• 50;
• amino acids 94 to 102 of SEQ ID NO:
• 50;
• amino acids 24 to 40 of SEQ ID NO:
• 52;
• amino acids 56 to 62 of SEQ ID NO:
• 52;
• amino acids 95 to 103 of SEQ ID NO:
• 52;
• amino acids 24 to 34 of SEQ ID NO:
• 54;
• amino acids 50 to 56 of SEQ ID NO:
• 54;
• amino acids 89 to 97 of SEQ ID NO:
• 54;
• amino acids 24 to 34 of SEQ ID NO:
• 56,
• amino acids 50 to 56 of SEQ ID NO:
• 56;
• amino acids 89 to 97 of SEQ ID NO:
• 56;
• amino acids 24 to 40 of SEQ ID NO:
• 58;
• amino acids 56 to 62 of SEQ ID NO:
• 58;
• amino acids 95 to 103 of SEQ ID NO:
• 58;
• amino acids 24 to 34 of SEQ ID NO:
• 60;
• amino acids 50 to 56 of SEQ ID NO:
• 60;
• amino acids 89 to 97 of SEQ ID NO:
• 60;
• amino acids 24 to 34 of SEQ ID NO:
• 62;
• amino acids 50 to 56 of SEQ ID NO:
• 62;
• amino acids 89 to 97 of SEQ ID NO:
• 62;
• amino acids 24 to 35 of SEQ ID NO:
• 64;
• amino acids 51 to 57 of SEQ ID NO:
• 64;
• amino acids 90 to 88 of SEQ ID NO:
• 64;
• amino acids 24 to 34 of SEQ ID NO:
• 66;
• amino acids 50 to 57 of SEQ ID NO:
• 66;
• amino acids 89 to 97 of SEQ ID NO:
• 66;
• amino acids 24 to 34 of SEQ ID NO:
• 68;
• amino acids 50 to 56 of SEQ ID NO:
• 68;
• and
• amino acids 89 to 97 of SEQ ID NO:
• 68;
• wherein the polypeptide, in association with an antibody heavy chain, binds TR-2.

An isolated polynucleotide comprising a sequence encoding a polypeptide comprising at least one complementarity determining region (CDR) selected from CDR1a, CDR2a, and CDR3a

• wherein CDR1a comprises the amino acid sequence a b c d e f g h i j k l, wherein amino acid a is glycine, amino acid b is selected from glycine, tyrosine, or phenylalanine;
• amino acid c is selected from serine or threonine;
• amino acid d is selected from isoleucine or phenylalanine;
• amino acid e is selected from serine, threonine, or asparagine;
• amino acid f is selected from serine, aspartic acid, tyrosine, asparagine, threonine, or glycine;
• amino acid g is selected from glycine, aspartic acid, or tyrosine;
• amino acid h is selected from glycine, aspartic acid, tyrosine, asparagine, or serine;
• amino acid i is selected from tyrosine, isoleucine, histidine, methionine, or tryptophan;
• amino acid j is selected from asparagine, tyrosine, histidine, serine, or phenylalanine;
• amino acid k is tryptophan or is not present;
• and amino acid l is serine or is not present;
• wherein CDR2a comprises the amino acid sequence m n o p q r s t u v w x y z a′ b′ c′, wherein amino acid m is selected from tryptophan, tyrosine, histidine, valine, glutamic acid, or serine;
• amino acid n is selected from methionine or isoleucine;
• amino acid o is selected from asparagine, tyrosine, serine, tryptophan, or histidine;
• amino acid p is selected from proline, tyrosine, serine, arginine, histidine, or asparagine;
• amino acid q is selected from asparagine, serine, or aspartic acid;
• amino acid r is selected from serine or glycine;
• amino acid s is selected from aspartic acid, serine, threonine, or arginine;
• amino acid t is selected from asparagine, threonine, alanine, isoleucine, or tyrosine;
• amino acid u is selected from threonine, tyrosine, leucine, lysine, asparagine, or isoleucine;
• amino acid v is selected from glycine, tyrosine, aspartic acid, or cysteine;
• amino acid w is selected from tyrosine or asparagine;
• amino acid x is selected from alanine or proline;
• amino acid y is selected from glutamine, serine, or aspartic acid;
• amino acid z is selected from lysine, leucine, or serine;
• amino acid a′ is selected from phenylalanine, lysine, or valine;
• amino acid b′ is selected from glutamine, serine, or lysine;
• and amino acid c′ is glycine or is not present;
• wherein CDR3a comprises the amino acid sequence d′ e′ f′ g′ h′ i′ j′ k′ l′ m′ n′ o′ p′ q′ r′ s′ t′ u′ v′ w′, wherein amino acid d′ is selected from tryptophan, aspartic acid, glycine, serine, or glutamic acid;
• amino acid e′ is selected from asparagine, aspartic acid, glycine, arginine, serine, valine, or leucine;
• amino acid f′ is selected from histidine, serine, alanine, tyrosine, proline, asparagine, glycine or threonine;
• amino acid g′ is selected from tyrosine, serine, alanine, arginine, tryptophan, glycine or valine;
• amino acid h′ is selected from glycine, alanine, serine, asparagine, methionine, tyrosine, tryptophan, cysteine, or aspartic acid;
• amino acid i′ is selected from serine, tryptophan, glycine, phenylalanine, aspartic acid, tyrosine, or threonine;
• amino acid j′ is selected from glycine, threonine, serine, leucine, valine, asparagine, tryptophan, or tyrosine;
• amino acid k′ is selected from serine, phenylalanine, aspartic acid, tryptophan, glycine, or tyrosine, or is not present;
• amino acid l′ is selected from histidine, aspartic acid, alanine, tryptophan, tyrosine, serine, phenylalanine, valine, or glycine, or is not present;
• amino acid m′ is selected from phenylalanine, tyrosine, glutamic acid, proline, aspartic acid, cysteine, isoleucine, or methionine, or is not present;
• amino acid n′ is selected from aspartic acid, phenylalanine, alanine, leucine, or serine, or is not present;
• amino acid o′ is selected from tyrosine, leucine, aspartic acid, phenylalanine, proline, or valine, or is not present;
• amino acid p′ is selected from leucine, aspartic acid, or tyrosine, or is not present;
• amino acid q′ is selected from serine or tyrosine, or is not present;
• amino acid r′ is tyrosine or is not present;
• amino acid s′ is selected from glycine or tyrosine, or is not present;
• amino acid t′ is selected from glycine or methionine, or is not present;
• amino acid u′ is selected from methionine or aspartic acid, or is not present;
• amino acid v′ is selected from aspartic acid or valine, or is not present;
• and amino acid w′ is valine or is not present;
• and
• wherein the polypeptide, in association with an antibody light chain, binds TR-2.

An isolated polynucleotide comprising a sequence encoding a polypeptide comprising at least one complementarity determining region (CDR) selected from CDR1b, CDR2b, and CDR3b

• wherein CDR1b comprises the amino acid sequence a1 b1 c1 d1 e1 f1 g1 h1 i1 j1 k1 l1 ml n1 o1 p1 q1, wherein amino acid a1 is selected from arginine or lysine;
• amino acid b1 is selected from threonine, alanine, or serine;
• amino acid c1 is serine;
• amino acid d1 is glutamine;
• amino acid e1 is selected from serine or glycine;
• amino acid f1 is selected from isoleucine, leucine, or valine;
• amino acid g1 is selected from serine, leucine, or arginine;
• amino acid h1 is selected from threonine, serine, isoleucine, asparagine, arginine, histidine, or tyrosine;
• amino acid i1 is selected from tyrosine, arginine, tryptophan, aspartic acid, or serine;
• j1 is selected from leucine, isoleucine, asparagine, tyrosine, or serine;
• amino acid k1 is selected from asparagine, glycine, valine, alanine, or leucine;
• amino acid l1 is selected from tyrosine, alanine, or asparagine, or is not present;
• amino acid m1 is selected from asparagine or lysine, or is not present;
• amino acid n1 is selected from tyrosine, asparagine, or isoleucine, or is not present;
• amino acid o1 is selected from leucine or tyrosine, or is not present;
• amino acid p1 is selected from aspartic acid or leucine, or is not present;
• and amino acid q1 is selected from valine, alanine, or threonine, or is not present;
• wherein CDR2b comprises the amino acid sequence r1 s1 t1 u1 v1 w1 x1, wherein amino acid r1 is selected from alanine, aspartic acid, leucine, tryptophan, glycine, or valine;
• amino acid s1 is selected from threonine, valine, glycine, or alanine;
• amino acid t1 is serine;
• amino acid u1 is selected from serine, asparagine, or threonine;
• amino acid v1 is selected from leucine, phenylalanine, or arginine;
• amino acid w1 is selected from glutamine, alanine, or glutamic acid;
• and amino acid x1 is selected from serine, arginine, or threonine;
• wherein CDR3b comprises the amino acid sequence y1 z1 a1′ b1′ c1′ d1′ e1′ f1′ g1′, wherein amino acid y1 is selected from glutamine, methionine, leucine, or histidine;
• amino acid z1 is selected from glutamine or lysine;
• amino acid a1′ is selected from serine, threonine, alanine, histidine, tyrosine, or phenylalanine;
• amino acid b1′ is selected from tyrosine, leucine, asparagine, or glycine;
• amino acid c1′ is selected from serine, glutamine, isoleucine, or lysine;
• amino acid d1′ is selected from threonine, phenylalanine, tyrosine, alanine, or serine;
• amino acid e1′ is proline;
• amino acid f1′ is selected from leucine, phenylalanine, tryptophan, serine, or arginine;
• and amino acid g1′ is selected from threonine or serine;
• and
• wherein the polypeptide, in association with an antibody heavy chain, binds TR-2.

An isolated anti-TR-2 antibody, comprising a variable region and a constant region, wherein the antibody comprises:

• (i) a first polypeptide comprising at least one complementarity determining region (CDR) selected from CDR1a, CDR2a, and CDR3a,
• wherein CDR1a comprises the amino acid sequence a b c d e f g h i j k l, wherein amino acid a is glycine, amino acid b is selected from glycine, tyrosine, or phenylalanine;
• amino acid c is selected from serine or threonine;
• amino acid d is selected from isoleucine or phenylalanine;
• amino acid e is selected from serine, threonine, or asparagine;
• amino acid f is selected from serine, aspartic acid, tyrosine, asparagine, threonine, or glycine;
• amino acid g is selected from glycine, aspartic acid, or tyrosine;
• amino acid h is selected from glycine, aspartic acid, tyrosine, asparagine, or serine;
• amino acid i is selected from tyrosine, isoleucine, histidine, methionine, or tryptophan;
• amino acid j is selected from asparagine, tyrosine, histidine, serine, or phenylalanine;
• amino acid k is tryptophan or is not present;
• and amino acid l is serine or is not present;
• wherein CDR2a comprises the amino acid sequence m n o p q r s t u v w x y z a′ b′ c′, wherein amino acid m is selected from tryptophan, tyrosine, histidine, valine, glutamic acid, or serine;
• amino acid n is selected from methionine or isoleucine;
• amino acid o is selected from asparagine, tyrosine, serine, tryptophan, or histidine;
• amino acid p is selected from proline, tyrosine, serine, arginine, histidine, or asparagine;
• amino acid q is selected from asparagine, serine, or aspartic acid;
• amino acid r is selected from serine or glycine;
• amino acid s is selected from aspartic acid, serine, threonine, or arginine;
• amino acid t is selected from asparagine, threonine, alanine, isoleucine, or tyrosine;
• amino acid u is selected from threonine, tyrosine, leucine, lysine, asparagine, or isoleucine;
• amino acid v is selected from glycine, tyrosine, aspartic acid, or cysteine;
• amino acid w is selected from tyrosine or asparagine;
• amino acid x is selected from alanine or proline;
• amino acid y is selected from glutamine, serine, or aspartic acid;
• amino acid z is selected from lysine, leucine, or serine;
• amino acid a′ is selected from phenylalanine, lysine, or valine;
• amino acid b′ is selected from glutamine, serine, or lysine;
• and amino acid c′ is glycine or is not present;
• wherein CDR3a comprises the amino acid sequence d′ e′ f′ g′ h′ i′ j′ k′ l′ m′ n′ o′ p′ q′ r′ s′ t′ u′ v′ w′, wherein amino acid d′ is selected from tryptophan, aspartic acid, glycine, serine, or glutamic acid;
• amino acid e′ is selected from asparagine, aspartic acid, glycine, arginine, serine, valine, or leucine;
• amino acid f′ is selected from histidine, serine, alanine, tyrosine, proline, asparagine, glycine or threonine;
• amino acid g′ is selected from tyrosine, serine, alanine, arginine, tryptophan, glycine or valine;
• amino acid h′ is selected from glycine, alanine, serine, asparagine, methionine, tyrosine, tryptophan, cysteine, or aspartic acid;
• amino acid i′ is selected from serine, tryptophan, glycine, phenylalanine, aspartic acid, tyrosine, or threonine;
• amino acid j′ is selected from glycine, threonine, serine, leucine, valine, asparagine, tryptophan, or tyrosine;
• amino acid k′ is selected from serine, phenylalanine, aspartic acid, tryptophan, glycine, or tyrosine, or is not present;
• amino acid l′ is selected from histidine, aspartic acid, alanine, tryptophan, tyrosine, serine, phenylalanine, valine, or glycine, or is not present;
• amino acid m′ is selected from phenylalanine, tyrosine, glutamic acid, proline, aspartic acid, cysteine, isoleucine, or methionine, or is not present;
• amino acid n′ is selected from aspartic acid, phenylalanine, alanine, leucine, or serine, or is not present;
• amino acid o′ is selected from tyrosine, leucine, aspartic acid, phenylalanine, proline, or valine, or is not present;
• amino acid p′ is selected from leucine, aspartic acid, or tyrosine, or is not present;
• amino acid q′ is selected from serine or tyrosine, or is not present;
• amino acid r′ is tyrosine or is not present;
• amino acid s′ is selected from glycine or tyrosine, or is not present;
• amino acid t′ is selected from glycine or methionine, or is not present;
• amino acid u′ is selected from methionine or aspartic acid, or is not present;
• amino acid v′ is selected from aspartic acid or valine, or is not present;
• and amino acid w′ is valine or is not present;
• and
• wherein the first polypeptide, in association with an antibody light chain, binds TR-2;
• and
• (ii) a second polypeptide comprising at least one complementarity determining region (CDR) selected from CDR1b, CDR2b, and CDR3b
• wherein CDR1b comprises the amino acid sequence a1 b1 c1 d1 e1 f1 g1 h1 i1 j1 k1 l1 m1 n1 o1 p1 q1, wherein amino acid a1 is selected from arginine or lysine;
• amino acid b1 is selected from threonine, alanine, or serine;
• amino acid c1 is serine;
• amino acid d1 is glutamine;
• amino acid e1 is selected from serine or glycine;
• amino acid f1 is selected from isoleucine, leucine, or valine;
• amino acid g1 is selected from serine, leucine, or arginine;
• amino acid h1 is selected from threonine, serine, isoleucine, asparagine, arginine, histidine, or tyrosine;
• amino acid i1 is selected from tyrosine, arginine, tryptophan, aspartic acid, or serine;
• j1 is selected from leucine, isoleucine, asparagine, tyrosine, or serine;
• amino acid k1 is selected from asparagine, glycine, valine, alanine, or leucine;
• amino acid l1 is selected from tyrosine, alanine, or asparagine, or is not present;
• amino acid m1 is selected from asparagine or lysine, or is not present;
• amino acid n1 is selected from tyrosine, asparagine, or isoleucine, or is not present;
• amino acid o1 is selected from leucine or tyrosine, or is not present;
• amino acid p1 is selected from aspartic acid or leucine, or is not present;
• and amino acid q1 is selected from valine, alanine, or threonine, or is not present;
• wherein CDR2b comprises the amino acid sequence r1 s1 t1 u1 v1 w1 x1, wherein amino acid r1 is selected from alanine, aspartic acid, leucine, tryptophan, glycine, or valine;
• amino acid s1 is selected from threonine, valine, glycine, or alanine;
• amino acid t1 is serine;
• amino acid u1 is selected from serine, asparagine, or threonine;
• amino acid v1 is selected from leucine, phenylalanine, or arginine;
• amino acid w1 is selected from glutamine, alanine, or glutamic acid;
• and amino acid x1 is selected from serine, arginine, or threonine;
• wherein CDR3b comprises the amino acid sequence y1 z1 a1′ b1′ c1′ d1′ e1′ f1′ g1′, wherein amino acid y1 is selected from glutamine, methionine, leucine, or histidine;
• amino acid z1 is selected from glutamine or lysine;
• amino acid a1′ is selected from serine, threonine, alanine, histidine, tyrosine, or phenylalanine;
• amino acid b1′ is selected from tyrosine, leucine, asparagine, or glycine;
• amino acid c1′ is selected from serine, glutamine, isoleucine, or lysine;
• amino acid d1′ is selected from threonine, phenylalanine, tyrosine, alanine, or serine;
• amino acid e1′ is proline;
• amino acid f1′ is selected from leucine, phenylalanine, tryptophan, serine, or arginine;
• and amino acid g1′ is selected from threonine or serine;
• and wherein the second polypeptide, in association with an antibody heavy chain, binds TR-2.

An isolated anti-TR-2 antibody, comprising a variable region and a constant region, wherein the antibody comprises:

• a first polypeptide comprising complementarity determining regions (CDRs) as set forth in SEQ ID NO:
• 2 and a second polypeptide comprising CDRs as set forth in SEQ ID NO:
• 36;
• a first polypeptide comprising complementarity determining regions (CDRs) as set forth in SEQ ID NO:
• 4 and a second polypeptide comprising CDRs as set forth in SEQ ID NO:
• 38;
• a first polypeptide comprising complementarity determining regions (CDRs) as set forth in SEQ ID NO:
• 6 and a second polypeptide comprising CDRs as set forth in SEQ ID NO:
• 40;
• a first polypeptide comprising complementarity determining regions (CDRs) as set forth in SEQ ID NO:
• 8 and a second polypeptide comprising CDRs as set forth in SEQ ID NO:
• 42;
• a first polypeptide comprising complementarity determining regions (CDRs) as set forth in SEQ ID NO:
• 10 and a second polypeptide comprising CDRs as set forth in SEQ ID NO:
• 44;
• a first polypeptide comprising complementarity determining regions (CDRs) as set forth in SEQ ID NO:
• 12 and a second polypeptide comprising CDRs as set forth in SEQ ID NO:
• 46;
• a first polypeptide comprising complementarity determining regions (CDRs) as set forth in SEQ ID NO:
• 14 and a second polypeptide comprising CDRs as set forth in SEQ ID NO:
• 48;
• a first polypeptide comprising complementarity determining regions (CDRs) as set forth in SEQ ID NO:
• 16 and a second polypeptide comprising CDRs as set forth in SEQ ID NO:
• 50;
• a first polypeptide comprising complementarity determining regions (CDRs) as set forth in SEQ ID NO:
• 18 and a second polypeptide comprising CDRs as set forth in SEQ ID NO:
• 52;
• a first polypeptide comprising complementarity determining regions (CDRs) as set forth in SEQ ID NO:
• 20 and a second polypeptide comprising CDRs as set forth in SEQ ID NO:
• 54;
• a first polypeptide comprising complementarity determining regions (CDRs) as set forth in SEQ ID NO:
• 22 and a second polypeptide comprising CDRs as set forth in SEQ ID NO:
• 56;
• a first polypeptide comprising complementarity determining regions (CDRs) as set forth in SEQ ID NO:
• 24 and a second polypeptide comprising CDRs as set forth in SEQ ID NO:
• 58;
• a first polypeptide comprising complementarity determining regions (CDRs) as set forth in SEQ ID NO:
• 26 and a second polypeptide comprising CDRs as set forth in SEQ ID NO:
• 60;
• a first polypeptide comprising complementarity determining regions (CDRs) as set forth in SEQ ID NO:
• 28 and a second polypeptide comprising CDRs as set forth in SEQ ID NO:
• 62;
• a first polypeptide comprising complementarity determining regions (CDRs) as set forth in SEQ ID NO:
• 30 and a second polypeptide comprising CDRs as set forth in SEQ ID NO:
• 64;
• a first polypeptide comprising complementarity determining regions (CDRs) as set forth in SEQ ID NO:
• 32 and a second polypeptide comprising CDRs as set forth in SEQ ID NO:
• 66;
• or a first polypeptide comprising complementarity determining regions (CDRs) as set forth in SEQ ID NO:
• 34 and a second polypeptide comprising CDRs as set forth in SEQ ID NO:
• 68.